Photographer: Zoltan Mathe / AFP / Getty Images
Photographer: Zoltan Mathe / AFP / Getty Images
AstraZeneca Plc’s coronavirus vaccine did better than expected in a US clinical trial, providing assurance on its safety and efficacy.
The image developed with Oxford University was 79% effective in preventing Covid-19, and an independent monitoring board found no safety concerns, the company said. said Monday. The shooting also protected everyone immunized against severe disease and death in a study of more than 30,000 volunteers.
The results should strengthen confidence in the product after confusion about its actual effectiveness and the best dosing schedule with an impact on takeover. The vaccine has faced many failures, most recently in terms of supply problems and possible side effects. Even after The European Medicines Agency said it was safe on Thursday, not all EU countries resumed vaccination due to concerns about reports of blood clots.
“Efficiency is better than we expected,” wrote Peter Welford, an analyst at Jefferies, in a note to customers. “Importantly, after the recent unfounded safety concerns in Europe, the study confirms the safety profile.”
Read more: EU regulator considers Astra safe, but recommends warning label
Astra shares rose 1.2% when trading in London.
Deliveries to the EU have fallen Astra has been at odds with the bloc and has led officials to oppose gun exports from the region, while trying to hold the company accountable.
Read more: The battle against vaccines heats up with EU deliveries ready to stop Britain
Clinical trials in the UK and Brazil last year produced a number of readings due to different dosage amounts and regimens used, and at least 10 EU countries initially approved the shot for under-65s.
Data confusion
Many have because he reversed that decision after several actual use data showed that the vaccine was effective for everyone. Older adults accounted for about one-fifth of the US test, which demonstrated 80% efficacy in that age group. Last year’s trials failed to provide conclusive data due to the lack of participants over the age of 65.
A number of cases involving severe blood clots found in individuals after their inoculation have also affected the image of the vaccine. More than a dozen countries suspended use of the shooting last week on reports. European Medicines Agency and UK regulatory authority said on Thursday that no definitive link could be established between the clots and the vaccine, and the benefits of using it continued to outweigh the risks. The review of the US study, which found no safety issues, specifically looked at blood clots.
Skepticism about the vaccine began last year. When Astra and Oxford reported for the first time the initial data from clinical trials conducted in the UK and Brazil in November last year, produced two very different efficacy readings of 62% and 90%. Due to a manufacturing error, one group of participants received a lower first dose, which resulted in a higher reading compared to those who received two standard doses. Further analysis suggested that the difference was the difference rather than the dosing gap, rather than the amount.
More than 70 countries globally have approved the use of Astra-Oxford, and the partners intend to produce up to three billion doses of vaccine this year.
The vaccine is particularly important for the global effort to end the pandemic, as it is easy to store and transport, and the company offers no profit during the crisis. Unlike vaccines in Pfizer Inc. and partner BioNTech SE and Moderna Inc., which must be kept frozen, the Astra picture can be kept at refrigerator temperature.
(Updates to add the analyst’s comment in the fourth paragraph, the actions in the fifth)